Breast cancer drug shows promise for treating, preventing progestin-dependent tumors
Wednesday, January 28, 2009 - 14:56
in Health & Medicine
Recent studies suggest that human breast cancer risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule drug that targets the most common mutated gene, p53, in human cancer cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.
Read the whole article on Physorg
More from Physorg
Related
- Breast cancer drug shows promise for treating, preventing progestin-dependent tumorsWed, 28 Jan 2009, 14:37:05 EST
- Asian spice could reduce breast cancer risk in women exposed to hormone replacement therapyMon, 13 Jul 2009, 12:43:20 EDT
- New evidence of hormone therapy causing breast cancer, Stanford professor saysWed, 4 Feb 2009, 17:44:21 EST
- Breast tenderness during hormone replacement therapy linked to elevated cancer riskMon, 12 Oct 2009, 16:34:43 EDT
- Hormone therapy associated with reduced colorectal cancer riskThu, 8 Jan 2009, 0:22:33 EST